Literature DB >> 3082919

Suppression of the growth hormone (GH) response to clonidine and GH-releasing hormone by exogenous GH.

J M Nakamoto, J M Gertner, C M Press, R L Hintz, R G Rosenfeld, M Genel.   

Abstract

GH release in response to clonidine and human GH-releasing hormone-(1-44) (hGHRH-44) was assessed in 11 boys (aged 7-14 yr) with short stature, who had normal GH secretion. The response to these 2 provocative stimuli was repeated after, respectively, 2 and 3 days of treatment with human GH (0.1 U/kg, im). Exogenous GH significantly blunted the response to both clonidine [the mean 2-h integrated serum GH concentration falling from 1050 +/- 350 (+/- SEM) to 749 +/- 297 ng/ml X min; P = 0.03] and hGHRH-44, the 2-h integrated GH concentration falling from 1553 +/- 358 to 547 +/- 202 ng/ml X min; (P = 0.03). Plasma insulin-like growth factor (IGF-II) concentrations did not change after GH administration. In contrast, plasma IGF-I (somatomedin-C) concentrations increased from 97 +/- 16 ng/ml before administration of GH to 142 +/- 32 ng/ml (P = 0.05) after two days and 149 +/- 23 ng/ml (P less than 0.01) after the third treatment day. However, no correlation was found between the changes in response to clonidine or hGHRH-44 and changes in circulating levels of IGF-I. Our data confirm the existence of GH-dependent feedback inhibition of GH release during childhood and suggest that this inhibition operates, at least in part, at the level of the pituitary. While participation of the IGFs/somatomedins in this feedback loop cannot be excluded, the inhibitory effects of exogenous GH do not depend directly on circulating plasma IGF-I or IGF-II levels.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082919     DOI: 10.1210/jcem-62-5-822

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Effect of a long-term methionyl growth hormone treatment on growth hormone releasing hormone-induced growth hormone secretion in patients with constitutional growth delay.

Authors:  A Sartorio; A Conti; F Morabito; G Faglia
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

Review 2.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

3.  Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice.

Authors:  S L Asa; K T Coschigano; L Bellush; J J Kopchick; S Ezzat
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Prior endurance exercise attenuates growth hormone response to subsequent resistance exercise.

Authors:  Kazushige Goto; Masao Higashiyama; Naokata Ishii; Kaoru Takamatsu
Journal:  Eur J Appl Physiol       Date:  2005-02-16       Impact factor: 3.078

5.  Differential effect of insulin-like growth factor-1 and growth hormone on hypothalamic regulation of growth hormone secretion in the rat.

Authors:  I Gil Ad; A Weizman; A Silbergeld; Z Dickerman; B Kaplan; Z Laron; Y Koch
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

6.  GHRH-induced GH responses during recombinant GH treatment in patients with short stature.

Authors:  A Sartorio; A Spada; A Conti; M Monzani; G Faglia
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

7.  Effect of growth hormone on short normal children.

Authors:  P C Hindmarsh; C G Brook
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-05

8.  Galanin infusion restores the blunted GH responses to GHRH administration during GH treatment in children with constitutional growth delay.

Authors:  A Sartorio; A Conti; M Monzani; G Faglia
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

Review 9.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

10.  Exogenous growth hormone administration does not inhibit the growth hormone response to hexarelin in normal men.

Authors:  M Cappa; S Setzu; S Bernardini; D Carta; G Federici; A Grossi; S Loche
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.